Dexamethasone phosphate
Based on 11 publication(s) in Google Scholar
Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.89%
- CAS 番号: 312-93-6
- 分子式: C22H30FO8P
- 分子量:472.44
-
保管条件:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
TGF-beta/Smad Compound Library
HY-L018
-
Clinical Compound Library
HY-L026
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Pediatric Drug Library
HY-L104
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 Dexamethasone phosphate
More- Nat Commun. 2021 Dec 9;12(1):7162. [Abstract]
- Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]
- Biomaterials. 2025 Sep 3:326:123680. [Abstract]
- Biomaterials. 2025 Jan:312:122742. [Abstract]
- MedComm. 2023 Jun 5;4(3):e293. [Abstract]
- Phytother Res. 2026 Apr;40(4):2143-2165. [Abstract]
- Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]
- PLoS Pathog. 2025 Aug 4;21(8):e1013390. [Abstract]
- Sci Rep. 2025 Oct 14;15(1):35928. [Abstract]
- NMR Biomed. 2026 Apr;39(4):e70254. [Abstract]
- J Neuroimmunol. 2026 Jan 15:410:578814. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
RT-PCR
-
WB
生物活性
Dexamethasone phosphate (1, 2, 4 μM; 23 h) does not induce cytotoxicity in BV-2 microglial cells[1].
Dexamethasone phosphate (1, 2, 4 μM; 3 h pre-incubation, followed by 24 h LPS co-incubation) dampens LPS-induced secretion of RANTES, TGF-β1, and NO in BV-2 microglial cells, while dexamethasone phosphate (4 μM; 24 h incubation alone) has no inhibitory effect on these mediators[1].
Dexamethasone phosphate (4 μM; 3 h pre-incubation, followed by 24 h LPS co-incubation) increases LPS-reduced production of IL-10 and MIP-1α in BV-2 microglial cells, while dexamethasone phosphate (4 μM; 24 h incubation alone) reduces IL-10 production in untreated BV-2 microglial cells[1].
Dexamethasone phosphate (4 μM; 3 h pre-incubation in lower chambers, followed by 18 h LPS co-incubation) mitigates LPS-induced migration of BV-2 microglial cells, while having no effect on migration of untreated BV-2 microglial cells when used at 4 μM for 18 h incubation alone[1].
Dexamethasone phosphate (1, 2, 4 μM; 3 h pre-incubation, followed by 30 min LPS co-incubation) ameliorates LPS-induced degradation of IRAK-1 and IRAK-4, and inhibits LPS-induced activation of TRAF6, p-TAK1, and p-JNK in BV-2 microglial cells[1].
Dexamethasone phosphate (5×10-6 M; 5-min intervals at 37°C) undergoes hydrolysis to Dexamethasone free alcohol in human whole blood in vitro with a first-order rate constant of 0.162 hr-1, which is 25-fold slower than its in vivo conversion rate[3].
Dexamethasone phosphate (200 μM; 7 h) shows good stability with limited hydrolysis when incubated with human, porcine, or rat dermis for 7 hours, with 72.5-82.2% of the prodrug remaining intact[4].
Dexamethasone phosphate (50.8-51.8% drug loading; heated at 20 °C min-1) intercalated into MgAl layered double hydroxides enhances the thermal stability of dexamethasone phosphate disodium, with its decomposition occurring at temperatures higher than those of free sexamethasone phosphate disodium[5].
Dexamethasone phosphate (50.8-51.8% drug loading) is successfully intercalated into MgAl layered double hydroxides via electrostatic interactions, with no denaturation of the drug molecules, as confirmed by preserved characteristic FT-IR bands and shifted phosphate group vibrations[5].
Dexamethasone phosphate (1.5 mg/mL; 50 hours) is efficiently encapsulated by the NPA2 coacervate, which mediates sustained release of the drug over 50 hours in a cell-free in vitro system[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Dexamethasone phosphate (0.25 mg/kg; i.p.; daily; 8 days) reduces inflammatory cell counts, Th2 cytokine levels, airway hyperresponsiveness, and lung tissue inflammation in ovalbumin-induced asthmatic Sprague-Dawley rats[5].
Dexamethasone phosphate (1.15 mg per dose; p.o.; on days 1, 3, and 5) via Dexamethasone phosphate coacervate significantly reduces acute colitis severity (mean histopathology score 0.500), restores gut barrier function and microbiota diversity, and lowers systemic drug exposure compared to equivalent Dex-P aqueous solution treatment[6].
Dexamethasone phosphate (~1.15 mg; p.o.; single administration) via NPA2 coacervate sustains serum Dexamethasone levels at a lower therapeutic range for over 40 h in healthy rats, reducing systemic drug exposure compared to Dexamethasone phosphate aqueous solution[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 4 weeks old, 110-130 g, specific-pathogen-free, ovalbumin-sensitized and challenged asthma model)[5]
-
Dosage:0.25 mg/kg
-
Administration:i.p.; daily; 8 days
-
Result:Reduced the number of inflammatory cells (eosinophils, macrophages, neutrophils) in bronchoalveolar lavage fluid.
Suppressed ovalbumin-induced elevations in IL-4 and IL-13 cytokine levels in bronchoalveolar lavage fluid.
Inhibited airway hyperresponsiveness to methacholine (with pulmonary resistance reduced compared to untreated ovalbumin-challenged rats).
Reduced peribronchial and perivascular inflammatory cell infiltration and airway wall thickness compared to untreated ovalbumin-challenged rats.
Showed lower efficacy across all measured endpoints compared to the intercalated Dexa-LDHs formulation.
-
Animal Model:Sprague Dawley (SD) (female, 8-12 weeks, 200-300 g, acute colitis induced by 4.5% dextran sulfate sodium in drinking water for 7 days)[6]
-
Dosage:1.15 mg per dose
-
Administration:p.o.; on days 1, 3, and 5
-
Result:Significantly alleviated colonic edema and diarrhea, with a lower colon (cecum) weight/length ratio compared to untreated colitic rats and rats treated with Dex-P aqueous solution.
Reduced mean histopathology score to 0.500, significantly lower than 3.000 in untreated colitic rats and 1.917 in rats treated with Dex-P aqueous solution.
Significantly reduced colonic myeloperoxidase (MPO) activity compared to untreated colitic rats.
Restored mRNA levels of tight junction-associated proteins ZO-1 and occludin-1 to levels closer to healthy rats, with significantly higher expression than untreated colitic rats and rats treated with Dex-P aqueous solution.
Significantly reduced local mRNA levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF compared to untreated colitic rats and rats treated with Dex-P aqueous solution.
Promoted anti-inflammatory M2 macrophage polarization (increased CD206 staining) and reduced pro-inflammatory M1 macrophage polarization (decreased iNOS staining), with significantly higher IL-10 levels and lower IL-1β/IL-6 levels than untreated colitic rats and rats treated with Dex-P aqueous solution.
Increased gut bacterial richness (observed operational taxonomic units, OTUs) and diversity (Chao and Shannon indices) compared to untreated colitic rats and rats treated with Dex-P aqueous solution, with gut microbiota composition clustering closely with healthy rats.
Sustained serum dexamethasone concentrations at a lower therapeutic level for over 40 h, with significantly lower peak serum levels than rats treated with Dex-P aqueous solution.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 312-93-6
-
性状 Solid
-
分子量 472.44
-
分子式 C22H30FO8P
-
Color White to off-white
-
SMILES
O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(COP(O)(O)=O)=O)=C1
-
別名
Dexamethasone 21-phosphate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. [Abstract]2021 Dec 9;12(1):7162. PMID: 34887414 -
Adv Sci (Weinh)
Emodin Alleviates Sepsis-Induced Multiorgan Damage by Inhibiting NETosis through Targeting Neutrophils BCL-10. [Abstract]2025 Aug 8:e17129. PMID: 40779122
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]
DXMS (2 mg/kg; twice daily; ip). Kaplan-Meier survival curves over a 7-day period comparing the Sham, CLP septic group, Emodin treatment group, and DXMS treatment group.
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]
DXMS (2 mg/kg; twice daily; ip). Histopathological images showing tissue morphology and injury in the lung, liver, spleen, and kidney across the four experimental groups.
-
Biomaterials
Polymer-based gene-drug co-delivery system effectively inhibits pathologic retinal neovascularization through dual anti-inflammatory and anti-neovascular actions. [Abstract]2025 Sep 3:326:123680. PMID: 40916239 -
Biomaterials
Single-dose of integrated bilayer microneedles for enhanced hypertrophic scar therapy with rapid anti-inflammatory and sustained inhibition of myofibroblasts. [Abstract]2025 Jan:312:122742. PMID: 39106821 -
MedComm
Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. [Abstract]2023 Jun 5;4(3):e293. PMID: 37287755
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: MedComm. 2023 Jun 5;4(3):e293. [Abstract]
Dexamethasone phosphate disodium (DXM, 5 mg/kg; i.p.; single dose) significantly alleviated tissue damage in acute lung injury (ALI).
-
Phytother Res
Chrysophanol Attenuates Glucocorticoid-Induced Osteoporosis by Targeting the E74-Like Factor 5/Osteoglycin-Regulated PI3K/AKT/mTOR Signaling Axis: An In Vitro and In Vivo Study. [Abstract]2026 Apr;40(4):2143-2165. PMID: 41657040 -
Biochem Pharmacol
Glucocorticoid impairs angiogenesis-dependent osteogenesis by downregulating EphB4 in endothelial cells. [Abstract]2025 Dec 2:244:117586. PMID: 41344513
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]
Masson-stained images of mice tibias. Masson staining indicated a marked decrease in new bone formation in DEX (Dexamethasone phosphate disodium, 1 mg/kg; i.p.; Once daily for 8 weeks)-treated mice.
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]
DEX (1 μM; 24 h). The mRNA expression levels of p53, p21 and p16 of bone ECs were detected via qRT-PCR.
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]
DEX (1 μM; 24 h). The protein expression of p53, p21, p16 and GAPDH was detected via Western blot and quantitative analysis.
-
PLoS Pathog
2025 Aug 4;21(8):e1013390. PMID: 40758741 -
Sci Rep
2025 Oct 14;15(1):35928. PMID: 41087401
Dexamethasone phosphate purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 14;15(1):35928. [Abstract]
Comparison of C3 mRNA levels between non-reactive astrocytes (Lucid), LPS-induced reactive astrocytes (LPS), and Dexamethasone phosphate disodium (DEX, 100 nM; 24 h)-reversed reactive astrocytes (LPS + DEX), with results normalized to the Lucid group (one-way ANOVA followed by Bonferroni post hoc test).
-
NMR Biomed
Therapeutic Effects Assessment in Acute Lung Injury Using Hyperpolarized 129Xe Magnetic Resonance. [Abstract]2026 Apr;39(4):e70254. PMID: 41790004 -
J Neuroimmunol
Prior dexamethasone exposure attenuates the therapeutic efficacy of mouse bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis by fostering a hostile immunological microenvironment. [Abstract]2026 Jan 15:410:578814. PMID: 41289704
溶剤 & 溶解度
DMSO : 5 mg/mL (10.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (289 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Hui B, et al. Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(9):1761-1768. [Content Brief]
[2]. Bossa F, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013;19(9):1872-1879. [Content Brief]
[3]. Hare LE, et al. Bioavailability of dexamethasone. II. Dexamethasone phosphate. Clin Pharmacol Ther. 1975 Sep;18(3):330-7. [Content Brief]
[4]. Cázares-Delgadillo J, et al. Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability and transport kinetics. Eur J Pharm Biopharm. 2010;75(2):173-178. [Content Brief]
[6]. Zhao P, et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Nat Commun. 2021;12(1):7162. Published 2021 Dec 9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1167 mL | 10.5834 mL | 21.1667 mL | 52.9168 mL |
| 5 mM | 0.4233 mL | 2.1167 mL | 4.2333 mL | 10.5834 mL | |
| 10 mM | 0.2117 mL | 1.0583 mL | 2.1167 mL | 5.2917 mL |
Powered by Bioz